v3.26.1
Capital Stock (Tables)
 12 Months Ended
Mar. 31, 2026
Equity [Abstract]  
Schedule of Common Stock Warrants Outstanding
At March 31, 2026, the following common stock warrants were outstanding:
Number of common shares
underlying warrants		Exercise price
per share		Expiration
date
2,788,620$0.001N/A
9,294,022$5.380(a)
11,265,086$8.87710/4/2028
(a) The warrants will expire 60 days after the later of (i) the date on which the Company first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 Phase 3 clinical trial of fasedienol for the acute treatment of anxiety in adults with SAD, which occurred in December 2025, and (ii) the date on which the Company first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 Phase 3 clinical trial of fasedienol for the acute treatment of anxiety in adults with SAD.
Schedule of Common Stock Reserved for Future Issuance
We had the following shares of common stock reserved for future issuance:
As of March 31,
20262025
Issuance of common stock upon exercise of outstanding stock options under the Amended and Restated 2016 Stock Incentive Plan and the Amended and Restated 2019 Omnibus Equity Incentive Plan and inducement awards granted outside of the 2019 Plan 4,457,368 3,239,642 
Issuance of common stock upon exercise of outstanding warrants43,907,097 43,952,783 
Equity awards available under the Amended and Restated 2019 Omnibus Equity Incentive Plan1,122,097 2,042,153 
Shares available for issuance under the 2019 Employee Stock Purchase Plan693,558 911,342 
Shares reserved under the Sales Agreement17,548,172 27,951,416 
67,728,292 78,097,336